Why did Evonik’s net profit fall 31% YoY in Q2 2026 despite strong operating performance?

Evonik’s net profit fell 31% year-over-year to €85 million in Q2 2026 primarily due to impairment charges related to the shutdown of its polyester business in the custom solutions segment and impairment losses on assets of its Oxeno (C4) business.

What are the key drivers behind Evonik’s upgraded full-year 2026 outlook, and how has the Middle East conflict influenced its business?

Evonik upgraded its full-year 2026 adjusted EBITDA guidance to €2.0–€2.2 billion (from €1.7–€2.0 billion) and raised its sales forecast to ~€15 billion (from €13.5–€14.5 billion), citing stronger-than-expected performance in H1 2026 driven by higher demand and selling prices since early March — a shift attributed to the Middle East conflict, which caused supply chain bottlenecks outside Europe, created an 'economic windfall', restrained Asian competitors via shipping disruptions around the Arabian Peninsula, and pushed raw material prices higher; the company described this as a 'fundamental' change in business development.

Evonik net profit hit by impairment charges, operating result beat estimates

Aug 4, 2026

Evonik Industries AG reported a 31% drop in Q2 net profit due to impairments, yet adjusted EBITDA beat estimates driven by higher volumes and prices. The company upgraded its 2026 outlook citing Middle East supply chain impacts and confirmed cost-cutting measures.

chemweek

Evonik net profit hit by impairment charges, operating result beats estimates

chemweek

Evonik Net Profit Falls 31% Amid Impairment Charges, Operating Result Beats Estimates

chemweek

2026-03-10

Evonik Maintains 2026 Profit Forecast

2026-04-28

Evonik to supply membrane technology to bioenergy firm in Malaysia

2026-05-13

Evonik Partners with MTCO for Biogas Purification